Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
(2014) In JAMA: The Journal of the American Medical Association 311(6). p.597-603- Abstract
- Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4334812
- author
- Herweijer, Eva ; Leval, Amy ; Ploner, Alexander ; Eloranta, Sandra ; Simard, Julia Fridman ; Dillner, Joakim LU ; Netterlid, Eva LU ; Sparén, Pär and Arnheim-Dahlström, Lisen
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Condylomata Acuminata: epidemiology, Condylomata Acuminata: prevention & control, Papillomavirus Infections: prevention & control, Papillomavirus Vaccines: administration & dosage, Registries: statistics & numerical data, Sweden: epidemiology, Uterine Cervical Neoplasms: prevention & control, Vaccination: statistics & numerical data
- in
- JAMA: The Journal of the American Medical Association
- volume
- 311
- issue
- 6
- pages
- 597 - 603
- publisher
- American Medical Association
- external identifiers
-
- pmid:24519299
- wos:000330941000015
- scopus:84893666624
- pmid:24519299
- ISSN
- 1538-3598
- DOI
- 10.1001/jama.2014.95
- language
- English
- LU publication?
- yes
- id
- dc33635d-238f-466e-b344-255141fe2306 (old id 4334812)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24519299?dopt=Abstract
- date added to LUP
- 2016-04-04 09:28:39
- date last changed
- 2022-04-23 20:45:14
@article{dc33635d-238f-466e-b344-255141fe2306, abstract = {{Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.}}, author = {{Herweijer, Eva and Leval, Amy and Ploner, Alexander and Eloranta, Sandra and Simard, Julia Fridman and Dillner, Joakim and Netterlid, Eva and Sparén, Pär and Arnheim-Dahlström, Lisen}}, issn = {{1538-3598}}, keywords = {{Condylomata Acuminata: epidemiology; Condylomata Acuminata: prevention & control; Papillomavirus Infections: prevention & control; Papillomavirus Vaccines: administration & dosage; Registries: statistics & numerical data; Sweden: epidemiology; Uterine Cervical Neoplasms: prevention & control; Vaccination: statistics & numerical data}}, language = {{eng}}, number = {{6}}, pages = {{597--603}}, publisher = {{American Medical Association}}, series = {{JAMA: The Journal of the American Medical Association}}, title = {{Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.}}, url = {{http://dx.doi.org/10.1001/jama.2014.95}}, doi = {{10.1001/jama.2014.95}}, volume = {{311}}, year = {{2014}}, }